Abstract:
|
The Prostate Biopsy Collaborative Group (PBCG) is an ongoing research project funded by the US National Cancer Institute to prospectively collect prostate biopsy outcomes and their risk factors from multiple international urologic centers. Its specific aims are to develop next generation prostate cancer risk assessment tools with increased accuracy due to the incorporation of novel individual- and clinic-risk factors, to appropriately convey inter-center variability in risk, and to provide automated re-calibration tools to tailor global risk tools to individual hospitals. In this poster, data from over 5,000 biopsies accrued during the first two years of the PBCG are summarized along with initial results from the planned methods of analysis.
|